Results of Ivivi Technology Demonstrate Acceleration in Pain Relief
Ivivi Technologies, Inc. (Northvale, NJ) recently announced the results of a randomized, double blind, placebo-controlled clinical study. “Effect of Pulsed Electromagnetic Fields (PEMF) on Post-Surgical Pain Reduction for Breast Augmentation” showed an 80% acceleration in pain relief among patients treated with this active technology compared to patients treated with placebos.
Patients were randomly assigned to active or placebo treatment with the wearable, lightweight, disposable Ivivi units, and assessed for postoperative pain twice daily for several days after surgery.
Ivivi’s proprietary PEMF technology is designed to accelerate the body’s natural anti-inflammatory response by exploiting the same basic electrochemical properties of the body that have been used diagnostically (CAT, MRI, and PET scans).
Visit http://www.ivivitechnologies.com/ for more information.
New V.A.C.® Therapy System Receives FDA Clearance
The US Food and Drug Administration (FDA) has cleared the new V.A.C.® Therapy Systems (Kinetic Concepts, Inc. San Antonio, Tex) across acute and homecare settings.
V.A.C. is an adjunctive wound treatment that utilizes subatmospheric pressure and consists of a vacuum pump, a collection canister, connection tubings, and specialized topical dressings.
The system includes the InfoV.A.C.™ Therapy System and the ActiV.A.C.™ System. The InfoV.A.C.™ is intended for use in acute care settings, is 50% lighter and smaller than its predecessor, and allows caregivers to monitor and document wound healing.
The ActiV.A.C.™ Therapy System automatically documents the patient’s therapy history and treatment times, which can be reviewed on screen or downloaded to a computer.
Visit http://www.kci1.com/ for more information.
Middle Eastern Wound Care Academy Concludes in Dubai
Smith & Nephew’s (London, England) first Wound Care Academy in Dubai was an educational initiative with special focus on the practical, clinical, and theoretical aspects of Advanced Wound Management. The week-long course was designed to increase awareness levels of wound management practices and principles among the local nursing staff.
Twenty-five nurses from Saudi Arabia, UAE, Bahrain, Qatar, Kuwait, Jordan, and Oman, attended the academy—all of whom have the desire to improve wound care in their communities and will return to their hospitals in efforts to train their colleagues.
Visit http://www.smith-nephew.com/ for more information.
Advanced Wound Care Technology Market to reach $4.6 billion in 2011
Reportbuyer.com (London, England) projects that the market for advanced wound care technology will reach $4.6 billion in 2011. In 2005, the market was worth more than $2.3 billion and over a 5 year period is predicted to have an average annual growth rate (AAGR) of 12.3%.
Report Buyer, the destination for business intelligence for major industry sectors recently added a new market report titled, “The Market for Advanced Wound Care Technology.” This report provides a quantitative market forecast for advanced wound care products, covers all key market segments, market analysis, and includes competitive analysis.
Visit http://www.reportbuyer.com for more information.
IYIA Launches Technology to Reduce Amputations due to Diabetic Foot Ulcers
IYIA Technologies Inc, (San Marcos, Calif) announces the launch of O2Misly™ for the treatment of nonhealing ulcers that offers a combination, adjunctive therapy to the standard of care.
O2Misly provides oxygen blended with a mist, which is infused under tension in a closed chamber, and also delivers an antimicrobial to the affected area.
In a clinical trial over the last 18 months, 75.5% of the patients treated with the device were healed within 12 weeks. All of the patients treated with O2Misly were healed within 20 weeks.
Visit http://www.iyiatechnologies.com for more information.
Intercytex Artificial Skin Produces Promising Results
Intercytex Group Plc (London, England) has developed a long lasting artificial skin called ICX-SKN that has produced promising results healing wounds in early clinical trials.
The artificial skin is more effective in comparison to other substitutes, which biodegrade in situ within a matter of weeks. ICX-SKN is made with a matrix produced by the same fibroblasts that are responsible for laying down collagen in natural skin.
Intercytex now plans to test ICX-SKN on larger wounds and advance to clinical trials that will generate sufficient data in order to seek a marketing license.
Visit http://www.intercytex.com for more information.
MÖlnlycke Advocates Use of Antimicrobial Soaps With CHG to Help Fight MRSA
New studies continue to indicate a rise in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA); however, antimicrobial skin cleansers containing the active ingredient chlorhexidine gluconate (CHG) are playing a key role in prevention.
A recent study released by the Association for Professionals in Infection Control and Epidemiology reports that US hospital patients are contracting MRSA at 10 times the rate that some health officials had previously estimated. Also noted, were the “community-associated” outbreaks that have occurred among sports teams and correctional facilities where the infection can spread easily.
Use of antimicrobial, antiseptic skin cleansers containing CHG, such as Hibiclens® (Mölnlycke, Norcross, Ga) may result in a reduction in the incidents of such infections because of the ability to kill germs on contact and bond to the skin to keep killing microorganisms up to 6 hours after washing.
A key to prevention of a MRSA infection is keeping hands clean to reduce the risk of cross-contamination. However, many of the products used by consumers do not contain pharmaceutical-quality, antimicrobial agents with residual activity.
Hibiclens, contains 4% CHG and had the lowest irritation potential of 12 antiseptics tested except for water, which served as the negative control.
Visit http://www.molnlycke.com for more information.
